Pharma / Biotech

Zerbaxa ASPECT-NP Trial Demonstrated Noninferiority to Meropenem for Ventilated Nosocomial Pneumonia

ECCMID 2019: Results of the ASPECT-NP trial showed that an investigational dose of Merck’s ceftolozane-tazobactam was noninferior to meropenem in treating adults with ventilated nosocomial pneumonia.

Source link

Related posts

DANDRUFF 2 IN 1 (Pyrithione Zinc) Shampoo [CVS Pharmnacy, Inc]

Newsemia

CRESEMBA (Isavuconazonium Sulfate) Capsule CRESEMBA (Isavuconazonium Sulfate) Injection, Powder, Lyophilized, For Solution [Astellas Pharma US, Inc.]

Newsemia

OXYBUTYNIN CHLORIDE Tablet [REMEDYREPACK INC.]

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World